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Abstract The biological effects of the HIV-1 accessory protein, 
Vpr, have been studied in yeast expression systems. In our 
previous study [1], employing the pCUPl-vpr copper-inducible 
expression cassette, Vpr was shown to cause growth arrest and 
structural defects. In this study yeast constitutively expressing 
vpr, through elevated copy number and/or elevated transcription 
levels, displayed no growth arrest in fermentative growth 
conditions while Vpr was produced at much lower levels than in 
the inducible expression system. However, such cells were 
respiratory deficient and unable to utilise ethanol or glycerol as 
the sole carbon source. They exhibited gross mitochondrial 
dysfunction displayed in the loss of respiratory chain complex I, 
II, III, IV and citrate synthase activities. The effects on 
mitochondria required a C-terminal domain of Vpr that contains 
a conserved amino acid sequence motif HFRIGCRHSRIG. 
These results suggest that the widely observed phenomenon of 
'Vpr-induced growth arrest' in human cells could be due to 
mitochondrial dysfunction. 
© 1997 Federation of European Biochemical Societies. 
Key words: A I D S ; Apoptosis; Growth arrest; H I V - 1 ; 
Mitochondria; Respiration; Vpr 
1. Introduction 
The HIV-1 viral protein R (Vpr) is a virion-associated pro-
tein whose mechanism of action has not yet been elucidated. 
Vpr is thought to influence the nuclear localization of viral 
nucleic acids in non-dividing host cells [2]; however, two ma-
jor effects on cell division and survival have not been ad-
equately explained. One effect, cell killing, is seen when Vpr 
or Vpr-related peptides are added externally [3,4]. The second 
effect, and the main subject of this report, is a growth arrest 
when vpr is expressed in cells. 
When vpr is transfected into normally dividing cells on an 
expression plasmid, vpr has the profound effect of blocking 
cell division. This has been observed in numerous human cells 
including rhabdomyosarcoma cells [5], osteosarcoma cells [5], 
lymphocytes [6-10], peripheral blood mononuclear cells [7] 
and HeLa cells [8,11,12]. The growth arrest would appear to 
result from an interaction with a basic cellular function be-
cause it can be readily observed in simple eukaryotes such as 
the budding yeast, Saccharomyces cerevisiae [1] and the fission 
yeast Schizosaccharomyces pombe [13]. 
Molecular deletion analysis has shown that the growth ar-
rest in yeast is due to the C-terminal region of Vpr, in partic-
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ular a repeated H(S/F)RIG amino acid sequence motif [1]. 
This region of Vpr is also incompatible with growth in 
HIV-1-infected cells since numerous HIV-1 clones produced 
in chronically infected, growing cells do not produce the C-
terminal, growth inhibitory port ion of Vpr [14,6]. 
This study addresses the mechanism of the growth arrest in 
a yeast system. Although a number of studies have concluded 
that Vpr induces an arrest in the G2 phase of cell growth [7-
13], our data provide evidence of an effect on mitochondria 
that would explain a subsequent G2 growth arrest. The pos-
sible consequences of the above findings for A I D S pathogen-
esis are discussed. 
2. Materials and methods 
2.1. Yeast growth and strains 
Two strains of the yeast Saccharomyces cerevisiae were employed 
for expression of vpr. Strain DY150 (MATa ura3-52 Ieu2-3,ll2 trpl-l 
ade2-\ his3-\\ canl-\00) has been described previously and is suited 
for the copper-inducible expression of vpr when preceded by the 
CUP1 promoter, pCUPl, as occurs in the plasmids utilised in this 
study [1]. The mutant strain PS145 (MATa ura3-\ leu2-3,112 trpl-l 
ade2-\ fcj-11,15 canl-100 HSF1::LEU2 [phsfl-206]) allows constit-
utive expression from pCUPl [15]. PS145 has a HSF1 gene disruption 
that would be normally be lethal except that in PS 145 it is comple-
mented by plasmid phsfl-206, a yeast shuttle plasmid with a TRP1 
marker. Thus, mutant strain PS 145 overproduces a mutant HSF1, in 
the place of a wild-type HSF1. pCUPl has a weak HSF1 binding 
sequence that is bound strongly by the mutant HSF1 leading to in-
creased constitutive transcription from pCUPl [15]. 
Media employed for the growth of yeast were the following: YEPD 
(1% yeast extract (Difco), 2% peptone, 2% dextrose); YEPE and 
YEPG were YEPD but with 2% ethanol or 3% glycerol substituted 
for dextrose; synthetic complete (0.67% yeast nitrogen base without 
amino acids (Difco), 2% dextrose, 20 u.g/ml adenine, 20 ug/ml histi-
dine, 20 ug/ml tryptophan, 20 ug/ml uracil and 20 ug/ml leucine); 
complete selective medium (synthetic complete lacking uracil and/or 
leucine) was used for the growth of transformants and was formulated 
to select for the plasmid in the transformants. Plasmid phsfl-206 
required no selection since it was essential for viability in strain 
PS145, which contains a lethal disruption of the chromosomal 
HSF1 gene. Media with added copper were solidified by the addition 
of Phytagar (GIBCO) while other media were solidified by the addi-
tion of agar (Difco). 
2.2. Cloning of HIV-1 vpr for expression in yeast 
The HIV-1 vpr gene was derived by DNA amplification using PCR 
from the molecular clone pNL4-3 and its sequence confirmed by nu-
cleotide sequencing [1]. Cloning of vpr into the yeast expression plas-
mids, pYEULCBX and pYEULCGT, has been described previously 
[1]. (The vectors pYEULCBX and pYEULCGT are available com-
mercially under the names pYEX-BX and pYEX-4T (AMRAD, Aus-
tralia, and CLONTECH, USA)). They are designed for the copper-
inducible production in yeast of native or glutathione-S-transferase 
(GST) fusion proteins, respectively. Thus, pYEULCBX.Vpr and 
pYEULCGT.Vpr direct the production of Vpr and GST-Vpr, respec-
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tively. VprBE constructs contain a BamHI-EcoRI fragment of vpr 
that directs the synthesis of a truncated protein lacking the C-terminal 
third of Vpr. 
Cloning into the yeast plasmid pYEL2 [16] is described in Fig. 1. 
The final construct utilised the CUPl-vpr expression unit employed in 
plasmid pYEULCBX.Vpr. pYEL2.Vpr is a vector that replicates to a 
very high level in absence of leucine. The pYEULCBX and 
pYEULCGT plasmids described above also have this capacity but 
pYEL2 plasmids exhibit a 2-fold higher copy number because of their 
smaller size [17]. Yeast transformants were obtained by lithium ace-
tate transformation [18], with slight modifications. pYEL2 transform-
ants were selected on complete selective medium plates containing all 
supplements required by the host except leucine. The pYEL2 trans-
formation frequency was low because of selection for the LEU2-d 
marker. Other transformants were initially selected on complete selec-
tive medium plates minus uracil, and leucine was omitted in subse-
quent culturing. 
2.3. Mitochondrial enzyme activities 
Mitochondria were prepared from cells grown in 500 ml of syn-
thetic complete medium. For induction 0.5 mM copper sulfate was 
added to cells in exponential growth phase and cultures were main-
tained for 16 h. Mitochondria were prepared from the cells by the 
method of Glick and Pons [19], and disrupted by two cycles of freez-
ing and thawing. Samples for assay of respiratory chain complex I 
and citrate synthase were further disrupted by sonication using a 
Branson B-30 sonifier with microtip (30 pulses at 30% duty cycle). 
Respiratory chain complexes I (NADH-coenzyme Qi reductase), II 
(succinate-coenzyme Qi reductase), III (decylubiquinol-cytochrome c 
reductase), IV (cytochrome c oxidase), and citrate synthase were as-
sayed as described by Rahman et al. [20]. Unlike mammalian cells and 
as reported previously [21], no rotenone-sensitive complex I activity 
was detected in S. cerevisiae, and the values reported for complex I 
activity are the total rates of NADH oxidation. 
3. Results 
3.1. Growth of Vpr transformants 
Plasmids described in this report were designed for copper-
inducible production of foreign proteins in a variety of labo-
ratory strains of Saccharomyces cerevisiae. As shown in Table 
1 the copper-induced production of Vpr or GST-Vpr in strain 
DY150, led to an arrest of cell growth, as observed previously 
[!]• 
The growth arrest with copper induction led us to expect 
that in a constitutive expression system there would be no 
survivors. As a means of testing the effects of the constitutive 
production of Vpr we transformed strain PS145, a yeast strain 
that allows constitutive expression from the CUP1 promoter. 
Although pCUPl is normally used for copper-inducible ex-
pression in yeast, strain PS145 encodes a mutant HSF1 that 
has high-affinity binding to a CUP1 HSE (heat shock element) 
Hindlll 
Kpnl 
(T4 polished) 
pCUPl 
V 
vpr tCUP1 
Fig. 1. Cloning of vpr expression cassette for higher levels of Vpr 
production in yeast. The vpr expression cassette (top) was obtained 
from pYEULCBX. Vpr [1] by digesting pYEULCBX.Vpr with Kpnl 
followed by treatment with T4 polymerase to render the DNA 
blunt-ended. After further digestion with Hindlll, the Hindlll-Kpnl 
(blunt-ended) fragment (vpr expression cassette) was isolated. It was 
ligated into pYEL2 that had been digested with Sacl followed by 
treatment with T4 polymerase to render the DNA blunt-ended, then 
followed by Hindlll digestion. ampr, ampicillin resistance gene; 
CUP1, copper metallothionein-encoding gene; LEU2-d, LEU2 gene 
encoding isopropyl-malate dehydrogenase with a truncated pro-
moter; vpr, HIV-1 gene encoding Vpr; ori, E. coli origin of DNA 
replication; ori2|i, yeast 2 |xm plasmid origin of DNA replication; 
p, promoter; t, transcription terminator; tef, tetracycline resistance 
gene. 
Table 1 
Growth of yeast transformants 
Transformant 
(Strain) [Plasmid] 
Growth on 
(YEPD or complete synthetic) (complete synthetic+copper) (YEPG or YEPE) 
DY150 [pYEULCBX] 
DY150 [pYEULCBX.Vpr] 
DY150 [pYEULCBX.VprBE] 
PS145 [pYEULCBX] + 
PS 145 [pYEULCBX.Vpr] + 
PS145 [pYEULCBX.Vpr] following plasmid shedding + 
DY150 [pYEL2] + 
DY150 [pYEL2.Vpr] + 
Freshly isolated yeast transformants were suspended in water and aliquots were dropped onto plates. Growth (+) or lack of growth (—) was scored 
after 3 days. Identical results were obtained when pYEULCGT (directs the production of a GST fusion protein), was used in place of pYEULCBX 
(directs the production of a native protein). 
I.G. Macreadie et al.lFEBS Letters 410 (1997) 145-149 147 
at random, all of the pYEL2 transformants were respiratory 
competent, while none of the pYEL2.Vpr transformants could 
grow on YEPE or YEPG. This provides a further evidence 
that Vpr causes a respiratory defect. 
YEPE plate 
Fig. 2. Respiratory deficiency associated with Vpr. The growth of 
PS145 yeast transformants on YEPD (fermentable carbon source) 
and YEPE (non-fermentable carbon source) plates are indicated. 
The transformants, PS145 [pYEULCGT], PS145 [pYEULCGT.Vpr], 
PS145 [pYEULCGT.VprBE], and PS145 [pYEULCGT.Vpr] after 
plasmid shedding, are indicated by the proteins they produce. 
and directs transcription from the CUP1 promoter [15]. 
pYEULCBX, pYEULCBX.Vpr, pYEULCGT and 
pYEULCGT.Vpr were transformed into PS 145 and URA+ 
transformants were selected. Transformants were picked 
onto a master plate of synthetic complete media lacking uracil 
and following growth they were replica plated to a variety of 
plates. Growth was normal when glucose was present but 
when glycerol or ethanol was present as the sole carbon 
source there was no growth (Table 1 and Fig. 2). This suggests 
that vpr causes a respiratory deficiency. The vpr-containing 
plasmid was shown to cause the respiratory deficiency when 
it was shed from PS 145 [pYEULCGT.Vpr] following growth 
on non-selective media. Colonies that shed plasmid 
pYEULCGT.Vpr regained wild-type respiratory function as 
judged by their growth on non-fermentable carbon sources 
(Table 1 and Fig. 2). 
The respiratory deficiency can be attributed to sequences in 
the C-terminal third of Vpr since constructs in which this 
region of Vpr was removed (e.g. pYEULCBX.VprBE and 
pYEULCGT.VprBE) exhibit normal respiratory growth like 
pYEULCBX and pYEULCGT transformants (Table 1). This 
region of Vpr is also involved in the growth arrest and ex-
tracellular activities [1,3,4] 
In case the respiratory defect could be an anomalous com-
plication resulting from the mutant HSF1 background vpr 
expression was re-examined in a strain wild-type for the 
HSF. Thus, vpr was recloned into pYEL2, a very high copy 
number plasmid, to direct high constitutive levels of Vpr pro-
duction in a wild-type HSF1 background (see Fig. 1). Of 48 
pYEL2 and 48 pYEL2.Vpr transformants that were sampled 
3.2. Production of Vpr with a GST fusion 
Due to its severe inhibitory effects on cell growth only mi-
nuscule amounts of Vpr have previously been produced in 
eukaryotic cell lines. Our work indicates that cells designed 
to produce Vpr, although respiratory deficient, can be grown 
in the presence of glucose and absence of copper. To ascertain 
that Vpr was being produced, we obtained yeast cell lysates of 
cells transformed with pYEULCGT.Vpr. First, amounts ob-
tained with copper-induced expression, where the cells become 
arrested were compared. Fig. 3 shows a comparison of the 
levels of GST (lanes 2), with GST-Vpr (lane 4) and GST-
Vpr truncated (lane 3) lacking the C-terminal portion of 
Vpr [1]. It is obvious that levels of GST and GST fusions 
produced during the two hours of copper induction are com-
parable despite the fact that the DY150 [pYEULCGT.Vpr] 
cells become growth arrested. Second, the levels of GST-Vpr 
in PS145 [pYEULCGT.Vpr] were considerably lower (lane 5) 
with constitutive expression. It appears that such lower levels 
of GST-Vpr are directly related to Vpr, since levels of GST 
(lane 6) are more like induced levels of GST and GST fusion 
proteins seen in lanes 2-A. 
In summary it appears that for the eukaryotic production 
of Vpr, yeast production presents attractive options with ei-
ther constitutive or inducible systems being demonstrated here 
as viable alternatives. Considering the growth advantages of 
respiratory competent strains, however, inducible systems may 
be preferred to avoid Vpr mutations. 
3.3. Transient respiratory deficiency 
Although the above-mentioned phenomena are clear, repro-
ducible and well supported by controls, we note that if the 
master plate is stored for some time and then re-replica 
plated, colonies that were previously respiratory deficient re-
grow on the plates with a non-fermentable carbon source. 
This happens in the absence of any changes to the vpr se-
quence, indicating that the loss of repiratory function is tran-
sient and may indicate that Vpr targets a step in mitochon-
drial function whose loss can be compensated for by another 
factor. This phenomenon must serve as a warning in the ex-
amination and interpretation of data pertaining to the effects 
of Vpr on cells, including mammalian cells. It is also wise to 
examine a number of transformants on an individual basis 
and to examine them without delay as compensatory changes, 
including deletion of vpr or sequences encoding the C-terminal 
region of Vpr may be employed by the cell to overcome the 
Table 2 
Mitochondrial enzyme activities in yeast transformants 
Mitochondrial enzyme activity 
(Complex I) (Complex II) 
Transformant 
(Strain) [Plasmid] 
Inducer 
(Complex III) (Complex IV) (Citrate synthase) 
DY150 [pYEULCBX] 
DY150 [pYEULCBX. Vpr] 
DY150 [pYEULCBX] + Cu2+ 
DY150 [pYEULCBX. Vpr] + Cu2+ 
655 
372 
325 
33 
7.6 
5.8 
4.9 
2.3 
7.45 
3.2 
2.9 
0.9 
20.9 
13.9 
8.1 
0.7 
139 
62 
56 
7 
Yeast transformants were grown in minimal selective medium overnight. Induction (+ Cu2+) was performed overnight with 0.5 mM CuSCv Units 
for enzyme activity are nmol/min/mg protein, except for complexes III and IV, which are expressed as apparent first-order rate constants (min -1 
mg-1). 
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Fig. 3. Expression of GST-Vpr in yeast. DY150 and PS145 trans-
formants were grown in complete selective medium. DY150 trans-
formants were induced for 2 h by the addition of 0.5 mM CUSO4 
to the culture media. Cell lysates were prepared by vortexing yeast 
cells with 0.5 mm glass beads for a total of 2 min. Lysates were 
then mixed with Laemmli loading buffer and fractionated by SDS-
PAGE gels (6-20% gradient gels Novex). The proteins were then 
transferred to nitrocellulose membranes and blotted with polyclonal 
antibody to GST. GST binding was detected by enhanced chemilu-
minescence (Amersham). The position of the pre-stained markers is 
shown. Lanes contain lysates from the following yeast transform-
ants: 1. DY150 [pYEULCBX]; 2. DY150 [pYEULCGT]; 3. DY150 
[pYEULCGT.VprBE]; 4. DY150 [pYEULCGT.Vpr]; 5. PS145 
[pYEULCGT.Vpr]; 6. PS145 [pYEULCGT]. 
toxic effects of Vpr. This has been observed on numerous 
occasions in the examination of human cells producing Vpr 
[6,14]. 
3.4. Multiple mitochondrial defects 
To obtain further information on the mitochondrial defect 
caused by Vpr we especially examined copper-induced cells 
because of their more reproducible phenotype. Copper addi-
tion to the control strain DY150 [pYEULCBX] caused a 
modest diminution of all mitochondrial enzyme activities 
measured, with residual activities of respiratory chain com-
plexes I to IV and citrate synthase ranging from 40% to 
65% of the 'no copper' sample (Table 2). Basal levels of 
Vpr expression in uninduced DY150 [pYEULCBX.Vpr] cells 
also appeared to cause a modest decrease in all mitochondrial 
enzymes with residual activities ranging from 40%> to 75%> of 
the control strain. In a comparison of the induced DY150 
[pYEULCBX. Vpr] strain with uninduced DY150 
[pYEULCBX] strain, activities of complexes I, III, IV and 
citrate synthase were decreased by 90-95% and complex II 
activity was decreased by 70%>. This confirms a simultaneous 
effect on numerous mitochondrial enzyme activities. 
4. Discussion 
The results presented here show that the production of 
HIV-1 Vpr in yeast causes a respiratory deficiency due to 
effects on five or more mitochondrial enzymes. This deficiency 
causes little interference with yeast growth on fermentable 
carbon sources such as glucose, but causes a complete block 
to growth on non-fermentable carbon sources such as glycerol 
or ethanol where mitochondrial respiratory function is re-
quired. Mitochondrial respiratory function has been tradition-
ally studied in yeast systems for almost five decades now so it 
is appropriate that yeast should provide this new unique in-
sight into Vpr function. The observation of multiple mito-
chondrial enzymic defects suggests that Vpr may target a ma-
jor control element such as a mitochondrial import receptor. 
In this respect it is interesting to note that Vpr contains two 
potential amphipathic helices. We can speculate that either of 
these sequences might compete with mitochondrial precursor 
proteins that utilise amphipathic helical leader sequences for 
their import into the mitochondrion. Second, it is of interest 
that there is a precedent for temporary respiratory deficiency 
of the type observed here. A genetic knockout of the Tom20, 
one component of the outer mitochondrial membrane import 
receptor, results in a respiratory deficiency that is only tem-
porary [22]. Further work will be directed toward determining 
the precise nature of the mitochondrial interaction. Previ-
ously, we did not observe the Vpr-related loss of respiratory 
function because the basal levels were too low to see a signifi-
cant effect, and with induction we obtained a total growth 
arrest. The total growth arrest could be due to very high 
Vpr levels and this could be further complicated by the pres-
ence of copper. 
It is highly relevant that during HIV-1 infection mitochon-
drial dysfunction can be observed in lymphocytes and other 
cells [23-31]. Our results suggest that Vpr could be the cause 
of such an effect. However, our results also suggest that the 
effects of Vpr on mitochondrial function could be dependent 
on a number of variable parameters. The effects could be 
transient as observed in yeast. In addition the effects would 
depend on the Vpr levels produced and on whether the Vpr 
contains the C-terminal domain containing the bioactive 
HFRIGCRHSRIG amino acid sequence. In our studies with 
human cells we have determined that the carbocyanine dye, 
DiSCa(5) (Molecular Probes), measures a rapid increase in 
mitochondrial membrane potential (Av|/m) preceding total col-
lapse of the potential and apoptosis, following the external 
addition of Vpr [4]. This result is consistent with a primary 
effect on mitochondria, as A\|/m disruption and subsequent 
nuclear apoptosis are strictly correlated [32]. It has been pro-
posed that mitochondrial disruption leads to the swelling, 
opening of the mitochondrial membrane transition pore and 
release of a cell suicide protein which causes apoptosis [33]. 
In summary, while previous studies have reported a Vpr-
related cell growth arrest, it is likely that this effect could be a 
consequence of an initial effect on mitochondrial function. 
The commonly reported G2 arrest may be an epiphenomenon, 
with mitochondrial respiratory function loss leading to apop-
tosis being the cause of cell cycle arrest, as fragmented DNA 
would prevent the cells from proceeding to mitosis [34,35]. 
The finding that Vpr causes mitochondrial dysfunction may 
aid the development of new strategies to overcome AIDS. 
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